1
|
Maulucci F, Disanto G, Bianco G, Pileggi M, Fischer U, Padlina G, Strambo D, Michel P, Kahles T, Nedeltchev K, Fisch U, Bonati L, Kägi G, Escribano Paredes JB, Carrera E, Nyffeler T, Bolognese M, Wegener S, Luft A, Schelosky L, Medlin F, von Reding A, Peters N, Renaud S, Mono ML, Remonda L, Machi P, Psychogios MN, Kaesmacher J, Mordasini P, Cereda CW. Endovascular therapy outcome in isolated posterior cerebral artery occlusion strokes: A multicenter analysis of the Swiss Stroke Registry. Eur Stroke J 2023; 8:575-580. [PMID: 37231695 PMCID: PMC10334166 DOI: 10.1177/23969873221150125] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2023] Open
Abstract
PURPOSE There is little data on the safety and efficacy of endovascular treatment (EVT) in comparison with intravenous thrombolysis (IVT) in acute ischemic stroke due to isolated posterior cerebral artery occlusion (IPCAO). We aimed to investigate the functional and safety outcomes of stroke patients with acute IPCAO treated with EVT (with or without prior bridging IVT) compared to IVT alone. METHODS We did a multicenter retrospective analysis of data from the Swiss Stroke Registry. The primary endpoint was overall functional outcome at 3 months in patients undergoing EVT alone or as part of bridging, compared with IVT alone (shift analysis). Safety endpoints were mortality and symptomatic intracranial hemorrhage. EVT and IVT patients were matched 1:1 using propensity scores. Differences in outcomes were examined using ordinal and logistic regression models. FINDINGS Out of 17,968 patients, 268 met the inclusion criteria and 136 were matched by propensity scores. The overall functional outcome at 3 months was comparable between the two groups (EVT vs IVT as reference category: OR = 1.42 for higher mRS, 95% CI = 0.78-2.57, p = 0.254). The proportion of patients independent at 3 months was 63.2% in EVT and 72.1% in IVT (OR = 0.67, 95% CI = 0.32-1.37, p = 0.272). Symptomatic intracranial hemorrhages were overall rare and present only in the IVT group (IVT = 5.9% vs EVT = 0%). Mortality at 3 months was also similar between the two groups (IVT = 0% vs EVT = 1.5%). CONCLUSION In this multicenter nested analysis, EVT and IVT in patients with acute ischemic stroke due to IPCAO were associated with similar overall good functional outcome and safety. Randomized studies are warranted.
Collapse
Affiliation(s)
- F Maulucci
- Stroke Centre, Neurology Department, Neurocentre of Southern Switzerland, EOC, Lugano, Switzerland
| | - G Disanto
- Stroke Centre, Neurology Department, Neurocentre of Southern Switzerland, EOC, Lugano, Switzerland
| | - G Bianco
- Stroke Centre, Neurology Department, Neurocentre of Southern Switzerland, EOC, Lugano, Switzerland
| | - M Pileggi
- Stroke Centre, Interventional and Diagnostic Neuroradiology, Neurocentre of Southern Switzerland, EOC, Lugano, Switzerland
| | - U Fischer
- Department of Neurology, University Hospital Bern, Bern, Switzerland
- Department of Neurology and Stroke Centre, University Hospital Basel, Basel, Switzerland
| | - G Padlina
- Department of Neurology, University Hospital Bern, Bern, Switzerland
| | - D Strambo
- Lausanne University Hospital, Stroke Centre, Neurology Service, Lausanne, Switzerland
| | - P Michel
- Lausanne University Hospital, Stroke Centre, Neurology Service, Lausanne, Switzerland
| | - T Kahles
- Department of Neurology, Kantonsspital Aarau, Aarau, Switzerland
| | - K Nedeltchev
- Department of Neurology, Kantonsspital Aarau, Aarau, Switzerland
| | - U Fisch
- Department of Neurology and Stroke Centre, University Hospital Basel, Basel, Switzerland
| | - L Bonati
- Department of Neurology and Stroke Centre, University Hospital Basel, Basel, Switzerland
| | - G Kägi
- Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland
| | | | - E Carrera
- Department of Neurology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - T Nyffeler
- Luzerner Kantonsspital, Centre of Neurology and Neurorehabilitation, Luzern, Switzerland
| | - M Bolognese
- Luzerner Kantonsspital, Centre of Neurology and Neurorehabilitation, Luzern, Switzerland
| | - S Wegener
- Universitätsspital Zürich, Neurology, Zürich, Switzerland
| | - A Luft
- Universitätsspital Zürich, Neurology, Zürich, Switzerland
| | - L Schelosky
- Kantonsspital Münsterlingen, Division of Neurology, Münsterlingen, Switzerland
| | - F Medlin
- Stroke Unit, Division of Neurology, HFR Fribourg, Fribourg, Switzerland
| | - A von Reding
- Neurology, Kantonsspital Winterthur, Winterthur, Switzerland
| | - N Peters
- Stroke Centre, Klinik Hirslanden, Zurich, Switzerland
| | - S Renaud
- Division of Neurology, Pourtalès Hospital, Neuchatel, Switzerland
| | - M-L Mono
- Stadtspital Waid und Triemli, Stroke Unit, Zürich, Switzerland
| | - L Remonda
- Department of Interventional Neuroradiology, Kantonsspital Aarau, Aarau, Switzerland
| | - P Machi
- Department of Interventional Neuroradiology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - M-N Psychogios
- Department of Interventional Neuroradiology, University Hospital Basel, Basel, Switzerland
| | - J Kaesmacher
- University Hospital Bern, Inselspital, Interventional Neuroradiology, Bern, Switzerland
| | - P Mordasini
- University Hospital Bern, Inselspital, Interventional Neuroradiology, Bern, Switzerland
| | - C W Cereda
- Stroke Centre, Neurology Department, Neurocentre of Southern Switzerland, EOC, Lugano, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
| |
Collapse
|
2
|
Reinmuth N, Cho B, Luft A, Alexander JA, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim F, Yang CT, Araujo L, Saito H, Barrett K, Lowery C, Tattersfield R, Peters S, Garon E, Mok T, Johnson M. 12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00266-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
3
|
Cho B, Luft A, Alatorre Alexander J, Lucien Geater S, Laktionov K, Sang-We K, Ursol G, Hussein M, Lim Farah L, Yang C, Araujo L, Saito H, Reinmuth N, Lai Z, Mann H, Shi X, Peters S, Garon E, Mok T, Johnson M. 326P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
4
|
Garon E, Cho B, Luft A, Alatorre-Alexander J, Geater S, Kim SW, Ursol G, Hussein M, Lim F, Yang CT, Araujo L, Saito H, Reinmuth N, Kohlmann M, Shi X, Mann H, Peters S, Mok T, Johnson M. EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
5
|
Peters S, Cho B, Luft A, Alatorre-Alexander J, Geater S, Kim SW, Ursol G, Hussein M, Lim F, Yang CT, Araujo L, Saito H, Reinmuth N, Stewart R, Lai Z, Doake R, Krug L, Garon E, Mok T, Johnson M. OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Novello S, Kowalski D, Luft A, Gumus M, Vicente Baz D, Mazieres J, Rodriguez Cid J, Tafreshi A, Cheng Y, Lee K, Golf A, Sugawara S, Robinson A, Halmos B, Jensen E, Schwarzenberger P, Pietanza M, Paz-Ares L. 974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
7
|
Garon E, Cho B, Luft A, Alatorre-Alexander J, Geater S, Trukhin D, Kim SW, Ursol G, Hussein M, Lim F, Yang CT, Araujo L, Saito H, Reinmuth N, Medic N, Mann H, Shi X, Peters S, Mok T, Johnson M. 5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
8
|
Filioglo A, Simaan N, Honig A, Heldner MR, von Rennenberg R, Pezzini A, Padjen V, Rentzos A, Altersberger VL, Baumgartner P, Zini A, Grisendi I, Aladdin S, Gomori JM, Pilgram-Pastor SM, Scheitz JF, Magoni M, Berisavac I, Nordanstig A, Psychogios M, Luft A, Gentile M, Assenza F, Arnold M, Nolte CH, Gamba M, Ercegovac M, Jood K, Engelter ST, Wegener S, Forlivesi S, Zedde M, Gensicke H, Tatlisumak T, Cohen JE, Leker RR. Outcomes after reperfusion therapies in patients with ACA stroke: A multicenter cohort study from the EVATRISP collaboration. J Neurol Sci 2022; 432:120081. [PMID: 34920158 DOI: 10.1016/j.jns.2021.120081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2021] [Revised: 11/28/2021] [Accepted: 12/01/2021] [Indexed: 11/19/2022]
Abstract
BACKGROUND Patients with stroke secondary to occlusions of the anterior cerebral artery (ACA) often have poor outcomes. The optimal acute therapeutic intervention for these patients remains unknown. METHODS Patients with isolated ACA-stroke were identified from 10 centers participating in the EndoVascular treatment And ThRombolysis in Ischemic Stroke Patients (EVATRISP) prospective registry. Patients treated with endovascular thrombectomy (EVT) were compared to those treated with intravenous thrombolysis (IVT). Odds ratios with 95% confidence intervals (OR; 95%CI) were calculated using multivariate regression analysis. RESULTS Included were 92 patients with ACA-stroke. Of the 92 ACA patients, 55 (60%) were treated with IVT only and 37 (40%) with EVT (±bridging IVT). ACA patients treated with EVT had more often wake-up stroke (24% vs. 6%, p = 0.044) and proximal ACA occlusions (43% vs. 24%, p = 0.047) and tended to have higher stroke severity on admission [NIHSS: 10.0 vs 7.0, p = 0.054). However, odds for favorable outcome, mortality or symptomatic intracranial hemorrhage did not differ significantly between both groups. Exploration of the effect of clot location inside the ACA showed that in patients with A1 or A2/A3 ACA occlusions the chances of favorable outcome were not influenced by treatment allocation to IVT or EVT. DISCUSSION Treatment with either IVT or EVT could be safe with similar effect in patients with ACA-strokes and these effects may be independent of clot location within the occluded ACA.
Collapse
Affiliation(s)
- A Filioglo
- Departments of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - N Simaan
- Departments of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - A Honig
- Departments of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - M R Heldner
- Department of Neurology, University Hospital Bern, Switzerland
| | - R von Rennenberg
- Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin Institute of Health, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| | - A Pezzini
- Department of Clinical and Experimental Sciences, Neurology Clinic, University of Brescia, Italy
| | - V Padjen
- Neurology Clinic, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - A Rentzos
- Department of Diagnostic and Interventional Neuroradiology, Sahlgrenska University Hospital and Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden
| | - V L Altersberger
- Stroke Center and Department of Neurology, University Hospital Basel and University of Basel, Switzerland
| | - P Baumgartner
- University Hospital Zurich and University of Zurich, Switzerland
| | - A Zini
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Department of Neurology and Stroke Center, Maggiore Hospital, Bologna, Italy
| | - I Grisendi
- Neurology Unit, Stroke Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - S Aladdin
- Departments of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - J M Gomori
- Radiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - S M Pilgram-Pastor
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
| | - J F Scheitz
- Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin Institute of Health, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| | - M Magoni
- U.O Vascular Neurology, Stroke Unit, ASST Spedali Civili, Brescia, Italy
| | - I Berisavac
- Neurology Clinic, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - A Nordanstig
- Department of Clinical Neurosciences, Institute of Neurosciences and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - M Psychogios
- Department of Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel and University of Basel, Switzerland
| | - A Luft
- University Hospital Zurich and University of Zurich, Switzerland
| | - M Gentile
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Department of Neurology and Stroke Center, Maggiore Hospital, Bologna, Italy
| | - F Assenza
- Neurology Unit, Stroke Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - M Arnold
- Department of Neurology, University Hospital Bern, Switzerland
| | - C H Nolte
- Department of Neurology, Charité-Universitätsmedizin Berlin, Center for Stroke Research, Berlin, Berlin Institute of Health, Berlin, Germany
| | - M Gamba
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
| | - M Ercegovac
- Neurology Clinic, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - K Jood
- Department of Clinical Neurosciences, Institute of Neurosciences and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - S T Engelter
- Stroke Center and Department of Neurology, University Hospital Basel and University of Basel, Switzerland; Neurology and Neurorehabilitation, University Department of Geriatric Medicine FELIX PLATTER, University of Basel, Switzerland
| | - S Wegener
- University Hospital Zurich and University of Zurich, Switzerland
| | - S Forlivesi
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Department of Neurology and Stroke Center, Maggiore Hospital, Bologna, Italy
| | - M Zedde
- Neurology Unit, Stroke Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - H Gensicke
- Stroke Center and Department of Neurology, University Hospital Basel and University of Basel, Switzerland; Neurology and Neurorehabilitation, University Department of Geriatric Medicine FELIX PLATTER, University of Basel, Switzerland
| | - T Tatlisumak
- Department of Clinical Neurosciences, Institute of Neurosciences and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - J E Cohen
- Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - R R Leker
- Departments of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
| |
Collapse
|
9
|
Yang JH, Luft A, De La Mora Jiménez E, Lee J, Koralewski P, Karadurmus N, Sugawara S, Livi L, Basappa N, Quantin X, Dudnik J, Moran Ortiz D, Mekhail T, Okpara C, Zimmer Z, Samkari A, Bhagwati N, Csőszi T. 120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.139] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
10
|
Johnson M, Cho B, Luft A, Alatorre-Alexander J, Geater S, Laktionov K, Vasiliev A, Trukhin D, Kim S, Ursol G, Hussein M, Lim F, Yang C, Araujo L, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon E, Mok T. PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.029] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, Zhang H, Shi M, Luft A, Wolf J, Antonia S, Nakagawa K, Fairchild J, Baudelet C, Pandya D, Doshi P, Chang H, Reck M. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331 ☆. Ann Oncol 2021; 32:631-641. [PMID: 33539946 DOI: 10.1016/j.annonc.2021.01.071] [Citation(s) in RCA: 137] [Impact Index Per Article: 45.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 01/13/2021] [Accepted: 01/17/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously treated SCLC. PATIENTS AND METHODS CheckMate 331 is a randomized, open-label, phase III trial of nivolumab versus standard chemotherapy in relapsed SCLC. Patients with relapse after first-line, platinum-based chemotherapy were randomized 1 : 1 to nivolumab 240 mg every 2 weeks or chemotherapy (topotecan or amrubicin) until progression or unacceptable toxicity. Primary endpoint was overall survival (OS). RESULTS Overall, 284 patients were randomized to nivolumab and 285 to chemotherapy. Minimum follow-up was 15.8 months. No significant improvement in OS was seen with nivolumab versus chemotherapy [median OS, 7.5 versus 8.4 months; hazard ratio (HR), 0.86; 95% confidence interval (CI), 0.72-1.04; P = 0.11]. A survival benefit with nivolumab was suggested in patients with baseline lactate dehydrogenase ≤ upper limit of normal and in those without baseline liver metastases. OS (nivolumab versus chemotherapy) was similar in patients with programmed death-ligand 1 combined positive score ≥1% versus <1%. Median progression-free survival was 1.4 versus 3.8 months (HR, 1.41; 95% CI, 1.18-1.69). Objective response rate was 13.7% versus 16.5% (odds ratio, 0.80; 95% CI, 0.50-1.27); median duration of response was 8.3 versus 4.5 months. Rates of grade 3 or 4 treatment-related adverse events were 13.8% versus 73.2%. CONCLUSION Nivolumab did not improve survival versus chemotherapy in relapsed SCLC. No new safety signals were seen. In exploratory analyses, select baseline characteristics were associated with improved OS for nivolumab.
Collapse
Affiliation(s)
- D R Spigel
- Oncology Department, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA.
| | - D Vicente
- Department of Medical Oncology, Hosp Univ Virgen Macarena, Seville, Spain
| | - T E Ciuleanu
- Medical Oncology, Prof. Dr. Ion Chiricuta Institute of Oncology and UMF Iuliu Hatieganu, Cluj-Napoca, Romania
| | - S Gettinger
- Medical Oncology, Yale Cancer Center, New Haven, USA
| | - S Peters
- Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
| | - L Horn
- Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, USA
| | | | - N Pardo Aranda
- Thoracic Unit, Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona
| | - O Juan-Vidal
- Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
| | - Y Cheng
- Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, Jilin, China
| | - H Zhang
- Department of Oncology, Tangdu Hospital, Xi'an, Shaanxi, China
| | - M Shi
- Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - A Luft
- Department of Thoracic Surgery, Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation
| | - J Wolf
- Clinic I for Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
| | - S Antonia
- Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Hospital, Osaka, Japan
| | - J Fairchild
- Clinical Development, Bristol Myers Squibb, Princeton, USA
| | - C Baudelet
- Global Drug Development, Biometrics & Data Sciences, Bristol Myers Squibb, Princeton, USA
| | - D Pandya
- Translational Pathology, Bristol Myers Squibb, Princeton, USA
| | - P Doshi
- Translational Medicine, Bristol Myers Squibb, Princeton, USA
| | - H Chang
- Translational Bioinformatics, Bristol Myers Squibb, Princeton, USA
| | - M Reck
- Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany
| |
Collapse
|
12
|
Kim H, Awad M, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema P, Rodriguez-Abreu D, Wollner M, Yang JH, Mazieres J, Orlandi F, Luft A, Gümüş M, Kato T, Kalemkerian G, Luo Y, Santorelli M, Pietanza M, Rudin C. 1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1544] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Pasquier P, Luft A, Gillard J, Boutonnet M, Vallet C, Pontier JM, Duron-Martinaud S, Dia A, Puyeo L, Debrus F, Prunet B, Beaume S, de Saint Maurice G, Meaudre E, Ficko C, Merens A, Raharisson G, Conte B, Dorandeu F, Canini F, Michel R, Ausset S, Escarment J. How do we fight COVID-19? Military medical actions in the war against the COVID-19 pandemic in France. BMJ Mil Health 2020; 167:269-274. [PMID: 32759228 DOI: 10.1136/bmjmilitary-2020-001569] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 07/06/2020] [Accepted: 07/06/2020] [Indexed: 01/06/2023]
Abstract
'We are at war', French President Emmanuel Macron said in an address to the nation on 16 March 2020. As part of this national effort, the French Military Medical Service (FMMS) is committed to the fight against COVID-19. This original report aimed to describe and detail actions that the FMMS has carried out in the nationwide fight against the COVID-19 pandemic in France, as well as overseas. Experts in the field reported major actions conducted by the FMMS during the COVID-19 pandemic in France. In just few weeks, the FMMS developed ad hoc medical capabilities to support national health authorities. It additionally developed adaptive, collective en route care via aeromedical and naval units and deployed a military intensive care field hospital. A COVID-19 crisis cell coordinated the French Armed Forces health management. The French Military Centre for Epidemiology and Public Health provided all information needed to guide the decision-making process. Medical centres of the French Armed Forces organised the primary care for military patients, with the widespread use of telemedicine. The Paris Fire Brigade and the Marseille Navy Fire Battalion emergency departments ensured prehospital management of patients with COVID-19. The eight French military training hospitals cooperated with civilian regional health agencies. The French military medical supply chain supported all military medical treatment facilities in France as well as overseas, coping with a growing shortage of medical equipment. The French Armed Forces Biomedical Research Institute performed diagnostics, engaged in multiple research projects, updated the review of the scientific literature on COVID-19 daily and provided expert recommendations on biosafety. Finally, even students of the French military medical academy volunteered to participate in the fight against the COVID-19 pandemic. In conclusion, in an unprecedented medical crisis, the FMMS engaged multiple innovative and adaptive actions, which are still ongoing, in the fight against COVID-19. The collaboration between military and civilian healthcare systems reinforced the shared objective to achieve the goal of 'saving the greatest number'.
Collapse
Affiliation(s)
- Pierre Pasquier
- Percy Military Training Hospital, French Military Health Service, Clamart, France .,Ecole du Val-de-Grâce French Military Medical Academy, Paris, France
| | - A Luft
- Direction Centrale du Service de Santé des Armées, Paris, France
| | - J Gillard
- Direction Centrale du Service de Santé des Armées, Paris, France
| | - M Boutonnet
- Percy Military Training Hospital, French Military Health Service, Clamart, France.,Ecole du Val-de-Grâce French Military Medical Academy, Paris, France
| | - C Vallet
- Service Médical de la Force d'Action Navale, French Military Health Service, Toulon, France
| | - J-M Pontier
- Cephismer, Centre d'Expertise Plongée pour la Marine Nationale, French Military Health Service, Toulon, France
| | | | - A Dia
- Centre d'épidémiologie et de Santé Publique des Armées, French Military Health Service, Marseille, France
| | - L Puyeo
- Direction de la Médecine des forces, French Military Health Service, Tours, France
| | - F Debrus
- Direction de la Médecine des forces, French Military Health Service, Tours, France
| | - B Prunet
- Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.,Emergency Department, Brigade de Sapeurs-Pompiers de Paris, Paris, France
| | - S Beaume
- Bataillon des Marins-Pompiers de Marseille, French Military Health Service, Marseille, France
| | - G de Saint Maurice
- Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.,Legouest Military Training Hospital, French Military Health Service, Metz, France
| | - E Meaudre
- Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.,Sainte-Anne Military Training Hospital, French Military Health Service, Toulon, France
| | - C Ficko
- Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.,Bégin Military Training Hospital, French Military Health Service, Saint-Mandé, France
| | - A Merens
- Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.,Bégin Military Training Hospital, French Military Health Service, Saint-Mandé, France
| | - G Raharisson
- Direction Centrale du Service de Santé des Armées, Paris, France
| | - B Conte
- Direction des approvisionnements en produits de santé des armées, French Military Health Service, Orléans, France
| | - F Dorandeu
- Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.,Institut de Recherche Biomédicale des Armées, French Military Health Service, Brétigny-sur-Orge, France
| | - F Canini
- Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.,Institut de Recherche Biomédicale des Armées, French Military Health Service, Brétigny-sur-Orge, France
| | - R Michel
- Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.,Écoles Militaires de Santé, French Military Health Service, Lyon-Bron, France
| | - S Ausset
- Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.,Écoles Militaires de Santé, French Military Health Service, Lyon-Bron, France
| | - J Escarment
- Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.,French Military Health Service, Paris, France
| |
Collapse
|
14
|
Reck M, Luft A, Bondarenko I, Shevnia S, Trukhin D, Kovalenko N, Vacharadze K, Andrea F, Hontsa A, Choi J, Shin D. A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.087] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Reinmuth N, Boothman AM, Cho B, Lee K, Luft A, Ahn MJ, Scott M, Whiteley J, Walker J, Karwe V, Mukhopadhyay P, Thiyagarajah P, Scheuring U, Rizvi N. PD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Rizvi N, Cho B, Reinmuth N, Lee K, Luft A, Ahn M, Papadimitrakopoulou V, Heymach J, Scheuring U, Higgs B, Ye J, Kuziora M, Wu S, Liu F, Si H, Peters S. OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.428] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Reinmuth N, Cho B, Lee K, Luft A, Ahn MJ, Schneider J, Shepherd F, Geater S, Pápai-Székely Z, Van Ngoc T, Garassino M, Liu F, Clemett D, Thiyagarajah P, Ouwens M, Scheuring U, Peters S, Rizvi N. Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz094.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
|
18
|
Cho B, Reinmuth N, Lee K, Ahn MJ, Luft A, Van den Heuvel M, Dols MC, Smolin A, Vicente D, Moiseyenko V, Antonia S, Moulec SL, Robinet G, Natale R, Garon E, Nakagawa K, Liu F, Thiyagarajah P, Peters S, Rizvi N. Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz094.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
|
19
|
Rizvi N, Chul Cho B, Reinmuth N, Lee K, Ahn MJ, Luft A, van den Heuvel M, Cobo M, Smolin A, Vicente D, Moiseyenko V, Antonia S, Le Moulec S, Robinet G, Natale R, Nakagawa K, Zhao L, Stockman P, Chand V, Peters S. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy511.005] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Kato T, Lee S, Cheng Y, Lee GW, Lee K, Luft A, Trigo J, Hui R, Balint B, Robinson A, Okamoto I, Gerstner G, Paz-Ares L, Li X, Shentu Y, Piperdi B, Tafreshi A. Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Mazières J, Kowalski D, Luft A, Vicente D, Tafreshi A, Gümüş M, Laktionov K, Hermes B, Cicin I, Rodríguez-Cid J, Wilson J, Kato T, Ramlau R, Novello S, Reddy S, Piperdi B, Li X, Burke T, Paz-Ares L. Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.074] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
22
|
Chau I, Al-Batran SE, Luft A, Kowalyszyn R, Hernandez C, Pfeiffer P, Wojcik E, Bodoky G, Madi A, Brenner B, De Vita F, Folprecht G, Peltola K, Lorenzen S, Denlinger C, Liepa A, Das M, Wei R, Fuchs C. Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Vitalis V, Carfantan C, Montcriol A, Peyrefitte S, Luft A, Pouget T, Sailliol A, Ausset S, Meaudre E, Bordes J. Early transfusion on battlefield before admission to role 2: A preliminary observational study during "Barkhane" operation in Sahel. Injury 2018; 49:903-910. [PMID: 29248187 DOI: 10.1016/j.injury.2017.11.029] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Revised: 11/10/2017] [Accepted: 11/22/2017] [Indexed: 02/02/2023]
Abstract
INTRODUCTION Haemorrage is the leading cause of death after combat related injuries and bleeding management is the cornerstone of management of these casualties. French armed forces are deployed in Barkhane operation in the Sahel-Saharan Strip who represents an immense area. Since this constraint implies evacuation times beyond doctrinal timelines, an institutional decision has been made to deploy blood products on the battlefield and transfuse casualties before role 2 admission if indicated. The purpose of this study was to evaluate the transfusion practices on battlefield during the first year following the implementation of this policy. MATERIALS AND METHODS Prospective collection of data about combat related casualties categorized alpha evacuated to a role 2. Battlefield transfusion was defined as any transfusion of blood product (red blood cells, plasma, whole blood) performed by role 1 or Medevac team before admission at a role 2. Patients' characteristics, battlefield transfusions' characteristics and complications were analysed. RESULTS During the one year study, a total of 29 alpha casualties were included during the period study. Twenty-eight could be analysed, 7/28 (25%) being transfused on battlefield, representing a total of 22 transfusion episodes. The most frequently blood product transfused was French lyophilized plasma (FLYP). Most of transfusion episodes occurred during medevac. Compared to non-battlefield transfused casualties, battlefield transfused casualties suffered more wounded anatomical regions (median number of 3 versus 2, p = 0.04), had a higher injury severity score (median ISS of 45 versus 25, p = 0,01) and were more often transfused at role 2, received more plasma units and whole blood units. There was no difference in evacuation time to role 2 between patients transfused on battlefield and non-transfused patients. There was no complication related to battlefield transfusions. Blood products transfusion onset on battlefield ranged from 75 min to 192 min after injury. CONCLUSION Battlefield transfusion for combat-related casualties is a logistical challenge. Our study showed that such a program is feasible even in an extended area as Sahel-Saharan Strip operation theatre and reduces time to first blood product transfusion for alpha casualties. FLYP is the first line blood product on the battlefield.
Collapse
Affiliation(s)
- V Vitalis
- French Medical Unit, Medical Centre of Lyon, France
| | - C Carfantan
- French Military Medical Service, Operational Headquarters, France
| | - A Montcriol
- Sainte Anne Military Teaching Hospital, Anaesthesia and Intensive Care Unit, Toulon, France
| | - S Peyrefitte
- French Medical Unit, Naval Special Operations Commandos Command, Lanester, France
| | - A Luft
- French Military Medical Service, Operational Headquarters, France
| | - T Pouget
- French Military Blood Institute, Clamart, France
| | - A Sailliol
- French Military Blood Institute, Clamart, France
| | - S Ausset
- Percy Military Teaching Hospital, Anaesthesia and Intensive Care Unit, Clamart, France & Val de Grâce Military Academy, Paris, France
| | - E Meaudre
- Sainte Anne Military Teaching Hospital, Anaesthesia and Intensive Care Unit, Toulon, France
| | - J Bordes
- Sainte Anne Military Teaching Hospital, Anaesthesia and Intensive Care Unit, Toulon, France; 7th Paratrooper Forward Surgical Unit, France.
| |
Collapse
|
24
|
Ajani J, Udrea A, Sarosiek T, Shenker M, Morgan C, Pikiel J, Wojcik E, Swinson D, Joseph M, Luft A, Salek T, Tournigand C, Ferry D, Zhang Y, Long A, Kuo WL, Gao L, Kauh J, Mansoor W. A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.082] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Abstract
Knowledge of performance can activate the striatum, a key region of the reward system and highly relevant for motivated behavior. Using functional magnetic resonance imaging, striatal activity linked to knowledge of performance was measured during the training of a repetitive arc-tracking task. Knowledge of performance was given after a random selection of trials or after good performance. The third group received knowledge of performance after good performance plus a monetary reward. Skill learning was measured from pre- to post- (acquisition) and from post- to 24h posttraining (consolidation). Our results demonstrate an influence of feedback on motor skill learning. Adding a monetary reward after good performance leads to better consolidation and higher ventral striatal activation than knowledge of performance alone. In turn, rewarding strategies that increase ventral striatal response during training of a motor skill may be utilized to improve skill consolidation.
Collapse
Affiliation(s)
- M Widmer
- University Hospital of Zurich, Zurich, Switzerland; Cereneo, Center for Neurology and Rehabilitation, Vitznau, Switzerland; Neural Control of Movement Lab, ETH Zurich, Zurich, Switzerland.
| | - N Ziegler
- Institute of Human Movement Sciences and Sport, ETH Zurich, Zurich, Switzerland
| | - J Held
- University Hospital of Zurich, Zurich, Switzerland; Cereneo, Center for Neurology and Rehabilitation, Vitznau, Switzerland
| | - A Luft
- University Hospital of Zurich, Zurich, Switzerland; Cereneo, Center for Neurology and Rehabilitation, Vitznau, Switzerland
| | - K Lutz
- University Hospital of Zurich, Zurich, Switzerland; Cereneo, Center for Neurology and Rehabilitation, Vitznau, Switzerland; Institute of Psychology, University of Zurich, Zurich, Switzerland
| |
Collapse
|
26
|
Reck M, Socinski M, Luft A, Szczesna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Brown J, Soldatenkova V, Chouaki N, Thatcher N. Quality-Of-Life (Qol), Tolerability, and Supportive Care Results: Necitumumab Phase 3 Squire Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Burkhardt J, Fierstra J, Esposito G, Luft A, Bozinov O, Regli L. Emergency Neurosurgical Bypass Revascularization for Acute Ischemic Stroke and Ruptured Complex Aneurysms. J Neurol Surg A Cent Eur Neurosurg 2014. [DOI: 10.1055/s-0034-1383756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Moncada-Torres A, Leuenberger K, Gonzenbach R, Luft A, Gassert R. Activity classification based on inertial and barometric pressure sensors at different anatomical locations. Physiol Meas 2014; 35:1245-63. [PMID: 24853451 DOI: 10.1088/0967-3334/35/7/1245] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Miniature, wearable sensor modules are a promising technology to monitor activities of daily living (ADL) over extended periods of time. To assure both user compliance and meaningful results, the selection and placement site of sensors requires careful consideration. We investigated these aspects for the classification of 16 ADL in 6 healthy subjects under laboratory conditions using ReSense, our custom-made inertial measurement unit enhanced with a barometric pressure sensor used to capture activity-related altitude changes. Subjects wore a module on each wrist and ankle, and one on the trunk. Activities comprised whole body movements as well as gross and dextrous upper-limb activities. Wrist-module data outperformed the other locations for the three activity groups. Specifically, overall classification accuracy rates of almost 93% and more than 95% were achieved for the repeated holdout and user-specific validation methods, respectively, for all 16 activities. Including the altitude profile resulted in a considerable improvement of up to 20% in the classification accuracy for stair ascent and descent. The gyroscopes provided no useful information for activity classification under this scheme. The proposed sensor setting could allow for robust long-term activity monitoring with high compliance in different patient populations.
Collapse
Affiliation(s)
- A Moncada-Torres
- Rehabilitation Engineering Laboratory, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
| | | | | | | | | |
Collapse
|
29
|
Luft A. Tierexperimentelle Modelle von Erholungsprozessen nach Schlaganfall. KLIN NEUROPHYSIOL 2013. [DOI: 10.1055/s-0033-1357212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- A. Luft
- Klinik für Neurologie, UniversitätsSpital Zürich und Universität Zürich, Schweiz
| |
Collapse
|
30
|
Sulzer J, Haller S, Scharnowski F, Weiskopf N, Birbaumer N, Blefari M, Bruehl A, Cohen L, deCharms R, Gassert R, Goebel R, Herwig U, LaConte S, Linden D, Luft A, Seifritz E, Sitaram R. Real-time fMRI neurofeedback: progress and challenges. Neuroimage 2013; 76:386-99. [PMID: 23541800 PMCID: PMC4878436 DOI: 10.1016/j.neuroimage.2013.03.033] [Citation(s) in RCA: 289] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2012] [Revised: 03/14/2013] [Accepted: 03/19/2013] [Indexed: 01/30/2023] Open
Abstract
In February of 2012, the first international conference on real time functional magnetic resonance imaging (rtfMRI) neurofeedback was held at the Swiss Federal Institute of Technology Zurich (ETHZ), Switzerland. This review summarizes progress in the field, introduces current debates, elucidates open questions, and offers viewpoints derived from the conference. The review offers perspectives on study design, scientific and clinical applications, rtfMRI learning mechanisms and future outlook.
Collapse
Affiliation(s)
- J. Sulzer
- Department of Health Sciences and Technology, Swiss Federal Institute of Technology, (ETH), Zurich CH-8092, Switzerland
| | - S. Haller
- University of Geneva, Geneva University Hospital CH-1211, Switzerland
| | - F. Scharnowski
- Department of Radiology and Medical Informatics - CIBM, University of Geneva, Switzerland
- Institute of Bioengineering, Swiss Institute of Technology Lausanne (EPFL) CH-1015, Switzerland
| | - N. Weiskopf
- Wellcome Trust Centre for Neuroimaging, UCL Institute of Neurology, University College London WC1E 6BT, UK
| | - N. Birbaumer
- The Institute of Medical Psychology and Behavioral Neurobiology, University of Tuebingen 72074, Germany
- Ospedale San Camillo, IRCCS, Venice 30126, Italy
| | - M.L. Blefari
- Department of Health Sciences and Technology, Swiss Federal Institute of Technology, (ETH), Zurich CH-8092, Switzerland
| | - A.B. Bruehl
- Department of Psychiatry, Psychotherapy and Psychosomatica, Zürich University Hospital for Psychiatry, Zurich CH-8032, Switzerland
| | - L.G. Cohen
- National Institutes of Health, Bethesda 20892, USA
| | | | - R. Gassert
- Department of Health Sciences and Technology, Swiss Federal Institute of Technology, (ETH), Zurich CH-8092, Switzerland
| | - R. Goebel
- Department of Neurocognition, University of Maastricht 6200, The Netherlands
| | - U. Herwig
- Department of Psychiatry, Psychotherapy and Psychosomatica, Zürich University Hospital for Psychiatry, Zurich CH-8032, Switzerland
- Department of Psychiatry and Psychotherapy III, University of Ulm, Germany
| | - S. LaConte
- Virginia Tech Carilion Research Institute 24016, USA
| | | | - A. Luft
- Department of Neurology, University Hospital Zurich, Switzerland
- University of Zurich CH-8008, Switzerland
| | - E. Seifritz
- Department of Psychiatry, Psychotherapy and Psychosomatica, Zürich University Hospital for Psychiatry, Zurich CH-8032, Switzerland
| | - R. Sitaram
- The Institute of Medical Psychology and Behavioral Neurobiology, University of Tuebingen 72074, Germany
- Department of Biomedical Engineering, University of Florida, Gainesville 32611, USA
- Sri Chitra Tirunal Institute of Medical Science and Technology, Trivandrum, India
| |
Collapse
|
31
|
Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2012; 24:75-83. [PMID: 22858559 DOI: 10.1093/annonc/mds213] [Citation(s) in RCA: 479] [Impact Index Per Article: 39.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Ipilimumab, an anti-CTLA4 monoclonal antibody, demonstrated survival benefit in melanoma with immune-related (ir) adverse events (irAEs) managed by the protocol-defined guidelines. This phase 2 study evaluated ipilimumab+paclitaxel (Taxol)/carboplatin in extensive-disease-small-cell lung cancer (ED-SCLC). DESIGN Patients (n=130) with chemotherapy-naïve ED-SCLC were randomized 1: 1: 1 to receive paclitaxel (175 mg/m2)/carboplatin (area under the curve=6) with either placebo (control) or ipilimumab 10 mg/kg in two alternative regimens, concurrent ipilimumab (ipilimumab+paclitaxel/carboplatin followed by placebo+paclitaxel/carboplatin) or phased ipilimumab (placebo+paclitaxel/carboplatin followed by ipilimumab+paclitaxel/carboplatin). Treatment was administered every 3 weeks for a maximum of 18 weeks (induction), followed by maintenance ipilimumab or placebo every 12 weeks. End points included progression-free survival (PFS), irPFS, best overall response rate (BORR); irBORR, overall survival (OS), and safety. RESULTS Phased ipilimumab, but not concurrent ipilimumab, improved irPFS versus control [HR (hazard ratio)=0.64; P=0.03]. No improvement in PFS (HR=0.93; P=0.37) or OS (HR=0.75; P=0.13) occurred. Phased ipilimumab, concurrent ipilimumab and control, respectively, were associated with median irPFS of 6.4, 5.7 and 5.3 months; median PFS of 5.2, 3.9 and 5.2 months; median OS of 12.9, 9.1 and 9.9 months. Overall rates of grade 3/4 irAEs were 17, 21 and 9% for phased ipilimumab, concurrent ipilimumab and control, respectively. CONCLUSION These results suggest further investigation of ipilimumab in ED-SCLC.
Collapse
Affiliation(s)
- M Reck
- Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Luft A, Pons Y. [Signs of upper airways digestive tract cancers and the general practitionner. Study of the practices by a Script Test Concordance]. Rev Laryngol Otol Rhinol (Bord) 2011; 132:131-136. [PMID: 22533064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
INTRODUCTION Upper Airways digestive tract cancers are the 4th more frequent cancer. They are responsible for non specific symptoms. The examination of this antomical region is very difficult for a general practitioner. The precoce diagnosis of these cancers is based on the good recognition of the clinical situations by the general practitioner. The aim of this study was to test the practice of the general practitioner in front of clinical situations typical of head and neck cancers by a Script test concordance. METHOD The study was performed on 107 parisian general practitioners who answered a questionnaire based on a Script Concordance Test (SCT). The SCT is a questionnaire that test the clinical way of thinking comparing the use of an information of experts versus non experts. RESULTS The answers of the practitioners tested were quite in accordance with the panel of experts' anwers. They were particularly good concerning the risk factors and the buccal and oropharyngeal cancers. The scores were lower concerning the nasopharyngeal, laryngeal and paranasal sinuses cancers. The scores were significantly better for the most experimented practitioners. DISCUSSION The fact that the rhinopharygeal, the laryngeal and the paranasal sinuses cancers are less frequent and the fact that these cancers can not be seen directly during a standard physical examination of general practitioner can explain the lower scores for these types of head and neck cancers. That is why practitioners have to be particularly aware of the symptoms and have to ask a specialized advice in case of doubt.
Collapse
Affiliation(s)
- A Luft
- Hôpital d'Instruction des Armées Percy, Service de Chirurgie Cervico-Faciale, 101 avenue Henri Barbusse, 92141 Clamart, France
| | | |
Collapse
|
33
|
Fantin G, Lecoules S, Carmoi T, Biale L, Luft A, Taillia H, Algayres JP. Face à la maladie de Basedow, il faut rechercher une myasthénie oculaire. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
34
|
Lynch TJ, Bondarenko IN, Luft A, Serwatowski P, Barlesi F, Chacko RT, Sebastian M, Siegel J, Cuillerot J, Reck M. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7531] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Nicaise A, Lecoules S, Carmoi T, Luft A, Biale L, Blondon H, Algayres JP. Thrombus intracardiaque révélateur d’une maladie de Behçet. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.10.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
36
|
Bigalke B, Stellos K, Geisler T, Kremmer E, Seizer P, May AE, Lindemann S, Melms A, Luft A, Gawaz M. Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. Eur J Neurol 2009; 17:111-7. [DOI: 10.1111/j.1468-1331.2009.02754.x] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
37
|
Ready N, Potti A, Karaseva N, Orlov S, Luft A, Popovych O, Liu PY, Holmlund JT, Wood BA, Leopold L. AT-101 or placebo (P) with docetaxel (D) in second-line NSCLC with gene signature biomarker development. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3577] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3577 Background: AT-101 inhibits the Bcl-2 protein family (Bcl-2, Bcl-xL, Mcl-1, Bcl-W) with broad preclinical activity including synergy with D. Methods: We conducted a randomized, double-blind, P-controlled phase 2 study. Patients had received 1 prior chemotherapy regimen for advanced NSCLC. Patients received AT-101 (40 mg b.i.d. days 1–3) or P with D (75 mg/m2 day 1) Q 21 days. Primary endpoint was progression-free survival (PFS) by independent review (IR). Secondary endpoints were overall survival (OS) and investigator determined PFS. 102 patients were planned for 70 events (80% power, HR 0.6, 1-sided alpha 0.1). A biomarker of AT-101 activity was developed by treating 55 NSCLC cell lines with AT-101 and using the corresponding gene expression data to identify a genomic predictor of sensitivity to AT-101. Results: 106 patients were randomized. Baseline factors were balanced. Median OS for patients on AT-101+D was 7.3 months versus 5.6 months for P + D arm (HR 0.60, p = 0.05). The median investigator determined PFS was 12.6 weeks and 10.7 weeks for AT-101+D and P+D arms respectively (HR 1.0, p = 0.49); IR is ongoing. Common adverse events were fatigue (18%), anemia (18%), and dyspnea (18%). Grade 1/2 headaches occurred more frequently in the AT-101 arm. Analysis of gene expression data by Bayesian regression revealed a robust 500 gene predictor of sensitivity to AT-101 that was cross validated in a leave one out analysis and in an independent cohort of 32 NSCLC cell lines. Validation of the predictor in patient samples from the trial is ongoing. Conclusions: In this phase II trial AT-101, an oral pan Bcl-2 family inhibitor, had favorable OS compared to placebo when combined with docetaxel in previously treated NSCLC and was well tolerated. A genomic predictor of AT-101 sensitivity is likely to enrich for responders and identify novel therapeutic combinations for future [Table: see text]
Collapse
Affiliation(s)
- N. Ready
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - A. Potti
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - N. Karaseva
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - S. Orlov
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - A. Luft
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - O. Popovych
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - P. Y. Liu
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - J. T. Holmlund
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - B. A. Wood
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| | - L. Leopold
- Duke University Medical Center, Durham, NC; St Petersburg City Clinical Oncology Center, St Petersburg, Russian Federation; State Higher Educational Institution, St Petersburg, Russian Federation; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation; Donetsk Regional Antitumor Center, Donetsk, Ukraine; Fred Hutchinson Cancer Research Center, Seattle, WA; Ascenta Therapeutics, Malvern, PA; Ascenta Therapeutics, Inc., Malvern, PA
| |
Collapse
|
38
|
Weiss D, Lam J, Luft A, Breit S, Gharabaghi A, Krüger R, Wächter T. Einfluss der Tiefen Hirnstimulation im Nucleus subthalamicus auf implizites Lernen bei M. Parkinson. KLIN NEUROPHYSIOL 2009. [DOI: 10.1055/s-0029-1216219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Whitall J, McCombe Waller S, Luft A, Hanley D. Verbesserung der motorischen Funktion nach bilateralem Armtraining bei chronischen mäßig schweren Folgen eines Schlaganfalls und damit einhergehende Reorganisation des Gehirns. physioscience 2006. [DOI: 10.1055/s-2006-926974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
40
|
Burk K, Globas C, Wahl T, Bühring U, Dietz K, Zuhlke C, Luft A, Schulz JB, Voigt K, Dichgans J. MRI-based volumetric differentiation of sporadic cerebellar ataxia. Brain 2004; 127:175-81. [PMID: 14570820 DOI: 10.1093/brain/awh013] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The term idiopathic cerebellar ataxia (IDCA) designates a variety of cerebellar syndromes that may present with a purely cerebellar syndrome (IDCA-C) or with additional extracerebellar features (IDCA-P). Multiple system atrophy is also a sporadic neurodegenerative disorder of unknown origin that may cause prominent cerebellar symptoms (MSA-C). The final neuropathological answer to the question whether IDCA-P and MSA-C represent different varieties of one disease or two distinct entities is still lacking. Three-dimensional MRI-based volumetry allows morphological investigations intra vitam. Volumetric analysis of cerebellum, brainstem and basal ganglia was therefore performed in 46 patients with sporadic cerebellar ataxia and 16 age-matched healthy controls. Patients with dementia were excluded from the study since cognitive impairment is an exclusion criterion for the diagnosis of MSA. Cerebellar patients were clinically divided into two groups: 33 patients with multiple system atrophy with prominent cerebellar symptoms (MSA-C) and 13 patients with extracerebellar features not corresponding to MSA-C (IDCA-P). There was evidence for substantial cerebellar atrophy in both cerebellar groups while additional brainstem atrophy was significantly more pronounced in MSA-C patients. Absolute caudate and putamen atrophy was found to be restricted to single MSA-C individuals while group comparisons of mean volumes did not yield significant differences from controls. Based on the volumetric data, diagnosis could be correctly predicted in 94% of control, 82% of MSA-C and 100% of IDCA-P individuals. The finding of specific imaging characteristics strengthens (i) the value of MRI volumetry in separating MSA-C from other types of sporadic cerebellar ataxia, and (ii) the hypothesis of two independent neurodegenerative disorders in MSA-C and IDCA-P.
Collapse
Affiliation(s)
- K Burk
- Department of Neurology, University of Tübingen, Hoppe-Seyler-Str. 3, D-72076 Tübingen, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Dally S, Luft A, Ponsin JC, Girre C, Mamo H, Fournier E. Abnormal pattern of cerebral blood flow distribution in young alcohol addicts. Br J Addict 1988; 83:105-9. [PMID: 3345373 DOI: 10.1111/j.1360-0443.1988.tb00458.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
43
|
George B, Zerah M, Luft A, Procyk T, Cophignon J. [Prognostic prediction of ruptured intracranial aneurysms]. Presse Med 1986; 15:1102. [PMID: 2942897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
|
44
|
Luft A, Tran-Dinh Y. [Microcomputers. Basic knowledge: the hardware]. Agressologie 1986; 27:33-9. [PMID: 3717510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
45
|
Blin F, Luft A, Blot P. [Survey of the role of computerization in departments of anesthesia-intensive care]. Agressologie 1985; 26:513-6. [PMID: 3840957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
46
|
Dematons C, Goldstein A, Muzard O, George B, Luft A, Raggueneau JL. [Treatment of vasospasm with beta-mimetics: study of cerebral blood flow]. Agressologie 1984; 25:823-6. [PMID: 6148901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
47
|
Goldstein A, Dematons C, Muzard O, George B, Roux FX, Luft A, Kind A, Raggueneau JL. [Perfusion pressure and cerebral blood flow in severe head injuries]. Agressologie 1984; 25:687-690. [PMID: 6486337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
48
|
Luft A, Meric P, Mamo H, George B, Raggueneau JL, Seylaz J, Rey A. [Measurement of loco-regional cerebral blood flow: an atraumatic method for neurophysiological study]. Agressologie 1984; 25:571-4. [PMID: 6486329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
49
|
Kaufmann HJ, Luft A, Schulze D. Deformation mechanism and dislocation structure of high-purity molybdenum single crystals at low temperatures. Cryst Res Technol 1984. [DOI: 10.1002/crat.2170190312] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
50
|
Mamo H, Meric P, Luft A, Seylaz J. Hyperfrontal pattern of human cerebral circulation. Variations with age and atherosclerotic state. Arch Neurol 1983; 40:626-32. [PMID: 6615269 DOI: 10.1001/archneur.1983.04050090062010] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The phenomenon of relative hyperperfusion of the frontal areas of the cerebral cortex (hyperfrontal flow distribution) was analyzed in 84 patients between 13 and 78 years of age. Fifty-two patients (group 1) had histories of vascular disease or vascular risk factors, and 32 (group 2) did not. Regional cerebral blood flow was measured by an atraumatic xenon Xe 133 method. The mean hemispheric gray-matter flow was found to decrease similarly with age in the two groups. Other findings were as follows: (1) the level of flow within the frontal region was not homogeneous in young adults; (2) in group 1, the frontal hyperperfusion decreased progressively with age, disappearing during the fifth and sixth decades according to a specific topographic pattern; (3) in group 2, hyperperfusion persisted into old age; and (4) hyperperfusion appeared more persistent with age in women than in men.
Collapse
|